{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T07:06:44Z","timestamp":1778569604210,"version":"3.51.4"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005047","name":"Natural Science Foundation of Liaoning Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005047","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      To evaluate the clinical efficacy, safety, and changes in the immune status of advanced non-small cell lung cancer (NSCLC) patients with disease progression after chemoradiotherapy treated with CT-guided\n                      <jats:sup>125<\/jats:sup>\n                      I radioactive seed implantation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>\n                      From January 2016 to June 2022, 34 NSCLC patients who progressed after radiotherapy and chemotherapy were studied retrospectively. There were 34 evaluable lesions, and\n                      <jats:sup>125<\/jats:sup>\n                      I seeds were implanted into the lesions under CT guidance. The study\u2019s endpoints were as follows: short-term clinical efficacy, quality of life score, and adverse reaction status assessment, with patients being collected for immune status assessment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The average postoperative follow-up period was 16.58 \u00b1 7.41 months. The 1-year postoperative survival rate was 76.47% (26\/34), the 2-year postoperative survival rate was 58.82% (20\/34), and the median overall survival was 16 (6\u201324) months (95% CI: 13.7\u201318.3). The 1-year progression-free survival (PFS) rate after the operation was 61.76% (21\/34), the 2-year PFS rate was 41.18% (14\/34), and the median PFS was 12.5 (1\u201324) months (95% CI: 10.8\u201316.2). Postoperative pneumothorax occurred in 11.76% of patients, minor bleeding in 5.88%, and pneumonia in 2.94%, all of which improved after symptomatic treatment. Compared with the preoperative results, the percentages of CD3\n                      <jats:sup>+<\/jats:sup>\n                      and CD4\n                      <jats:sup>+<\/jats:sup>\n                      T lymphocytes in the treatment group increased 1, 2, 3, and 6 months after surgery; the percentage of NK cells increased 3 and 6 months after surgery. The positive immune factor levels of IL-2 and TNF-\u03b1 were increased at 2, 3, and 6 months after surgery; \u03b3-IFN levels were increased at 1, 2, 3, and 6 months after surgery; IL-4 levels were decreased at 3 and 6 months after surgery; and IL-10 levels were decreased at 6 months after surgery. TH17 (IL-17) levels decreased at 1, 2, 3, and 6 months after surgery.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      CT-guided\n                      <jats:sup>125<\/jats:sup>\n                      I particle therapy may be an effective treatment for NSCLC that has progressed following radiotherapy and chemotherapy. Local treatments improve patients\u2019 quality of life and reduce tumor burden. CT-guided\n                      <jats:sup>125<\/jats:sup>\n                      I radioactive seed implantation may improve the immune status of patients with recurrent or progressive NSCLC after radiotherapy and chemotherapy and may enhance the antitumor immune response.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2025.1667205","type":"journal-article","created":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T05:29:22Z","timestamp":1762406962000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Analysis of short-term clinical efficacy and immune function changes of advanced non-small cell lung cancer after radiotherapy or chemotherapy under CT-guided 125I seed implantation"],"prefix":"10.3389","volume":"15","author":[{"given":"Songbai","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunfeng","family":"Kou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuting","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guangsheng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruoyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhe","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA: Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1080\/10463356.2022.2030612","article-title":"Interpretation of updated points of 2021 CSCO guideline for non-small-cell lung cancer","volume":"37","author":"Jia","year":"2022","journal-title":"J J Pract Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S174457","article-title":"Efficacy and safety of iodine-125 brachytherapy combined with chemotherapy in the treatment of advanced NSCLC in the elderly","volume":"11","author":"Wu","year":"2018","journal-title":"OncoTargets Ther"},{"key":"B4","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1007\/s00408-020-00407-5","article-title":"Update 2020: management of non-small cell lung cancer","volume":"198","author":"Alexander","year":"2020","journal-title":"Lung"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e65","DOI":"10.1056\/NEJMicm0810650","article-title":"Images in clinical medicine. Radiation pneumonitis after radiotherapy for breast cancer","volume":"361","author":"Bolke","year":"2009","journal-title":"New Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00470","article-title":"Oligorecurrence non-small cell lung cancer after failure of first-line chemotherapy: computed tomography-guided (125)I seed implantation vs. second-line chemotherapy","volume":"10","author":"Wang","year":"2020","journal-title":"Front Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.11655\/ajtr.2019.11.3737","article-title":"Therapy of (125)I particles implantation inhibited the local growth of advanced non-small cell lung cancer: a retrospective clinical study","volume":"11","author":"Dai","year":"2019","journal-title":"Am J Transl Res"},{"key":"B8","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1093\/jjco\/hyaa029","article-title":"Modern development of high-dose-rate brachytherapy","volume":"50","author":"Itami","year":"2020","journal-title":"Japanese J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.753286","article-title":"Precision interventional brachytherapy: A promising strategy toward treatment of Malignant tumors","volume":"11","author":"He","year":"2021","journal-title":"Front Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13143493","article-title":"Stereotactic ablative brachytherapy: recent advances in optimization of radiobiological cancer therapy","volume":"13","author":"Xue","year":"2021","journal-title":"Cancers"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2019.04.020","article-title":"Immunological consequences of chemotherapy: Single drugs, combination therapies and nanoparticle-based treatments","volume":"305","author":"Pusuluri","year":"2019","journal-title":"J Controlled Release: Off J Controlled Release Soc"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.2756","article-title":"Role of local radiation therapy in cancer immunotherapy","volume":"1","author":"Demaria","year":"2015","journal-title":"JAMA Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/09553002.2021.1910377","article-title":"Reconciling two opposing effects of radiation therapy: stimulation of cancer cell invasion and activation of anti-cancer immunity","volume":"97","author":"Oweida","year":"2021","journal-title":"Int J Radiat Biol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1118\/1.597458","article-title":"Dosimetry of interstitial brachytherapy sources: recommendations of the AAPM Radiation Therapy Committee Task Group No. 43. American Association of Physicists in Medicine","volume":"22","author":"Nath","year":"1995","journal-title":"Med Phys"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1118\/1.598721","article-title":"Permanent prostate seed implant brachytherapy: report of the American Association of Physicists in Medicine Task Group No. 64","volume":"26","author":"Yu","year":"1999","journal-title":"Med Phys"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1118\/1.1646040","article-title":"Update of AAPM Task Group No. 43 Report: A revised AAPM protocol for brachytherapy dose calculations","volume":"31","author":"Rivard","year":"2004","journal-title":"Med Phys"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_201441","article-title":"Tumor response assessment for precision cancer therapy: response evaluation criteria in solid tumors and beyond","volume":"38","author":"Nishino","year":"2018","journal-title":"Am Soc Clin Oncol Educ Book Am Soc Clin Oncol Annu Meeting"},{"key":"B18","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.brachy.2017.11.017","article-title":"Comparing the RTOG\/EORTC and LENT-SOMA scoring systems for the evaluation of late skin toxicity after (125)I seed brachytherapy for parotid gland cancer","volume":"17","author":"Mao","year":"2018","journal-title":"Brachytherapy"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11061738","article-title":"Real-world journey of unresectable stage III NSCLC patients: current dilemmas for disease staging and treatment","volume":"11","author":"Agbarya","year":"2022","journal-title":"J Clin Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-20-638","article-title":"A narrative review of toxicity of chemoradiation and immunotherapy for unresectable, locally advanced non-small cell lung cancer","volume":"9","author":"Prasad","year":"2020","journal-title":"Transl Lung Cancer Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-20-453","article-title":"Salvage surgery after definitive chemoradiotherapy for patients with non-small cell lung cancer","volume":"10","author":"Hamada","year":"2021","journal-title":"Transl Lung Cancer Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.athoracsur.2021.10.036","article-title":"Salvage surgery compared to surgery after induction chemoradiation therapy for advanced lung cancer","volume":"112","author":"Kobayashi","year":"2021","journal-title":"Ann Thorac Surg"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3390\/life12020292","article-title":"Toxicity of proton therapy versus photon therapy on salvage re-irradiation for non-small cell lung cancer","volume":"12","author":"Yang","year":"2022","journal-title":"Life (Basel Switzerland)"},{"key":"B24","doi-asserted-by":"publisher","first-page":"S2522","DOI":"10.21037\/jtd.2017.12.50","article-title":"Reirradiation for locoregionally recurrent non-small cell lung cancer","volume":"10","author":"Vyfhuis","year":"2018","journal-title":"J Thorac Dis"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2017.12.010","article-title":"Second-line treatment options in non-small-cell lung cancer: report from an international experts panel meeting of the Italian association of thoracic oncology","volume":"19","author":"Gridelli","year":"2018","journal-title":"Clin Lung Cancer"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.4103\/jcrt.JCRT_434_19","article-title":"Expert consensus on computed tomography-assisted three-dimensional-printed coplanar template guidance for interstitial permanent radioactive (125)I seed implantation therapy","volume":"15","author":"Wang","year":"2019","journal-title":"J Cancer Res Ther"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3779\/j.issn.1009-3419.2020.103.04","article-title":"Therapeutic effect of CT-guided \u00b9\u00b25I seed implantation on advanced lung cancer and pulmonary metastatic carcinoma","volume":"23","author":"Wang","year":"2020","journal-title":"Zhongguo fei ai za zhi = Chin J Lung Cancer"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.brachy.2016.02.001","article-title":"Effectiveness and safety of CT-guided (125)I seed brachytherapy for postoperative locoregional recurrence in patients with non-small cell lung cancer","volume":"15","author":"Huo","year":"2016","journal-title":"Brachytherapy"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/JLB.MR0318-097R","article-title":"T lymphocyte subsets in cancer immunity: Friends or foes","volume":"105","author":"Chraa","year":"2019","journal-title":"J Leukocyte Biol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.669474","article-title":"Differentiation and regulation of T(H) cells: A balancing act for cancer immunotherapy","volume":"12","author":"Basu","year":"2021","journal-title":"Front Immunol"},{"key":"B31","article-title":"IL-2 promotes macrophage M1 polarization via the Jak3-Stat5 signal pathway","volume":"35","author":"Wenjing","year":"2015","journal-title":"Basic Clin Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01170","article-title":"TNF receptor 2 makes tumor necrosis factor a friend of tumors","volume":"9","author":"Sheng","year":"2018","journal-title":"Front Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-017-2043-6","article-title":"IL-4 blockade alters the tumor microenvironment and augments the response to cancer immunotherapy in a mouse model","volume":"66","author":"Ito","year":"2017","journal-title":"Cancer Immunol Immunother: CII"},{"key":"B34","doi-asserted-by":"publisher","first-page":"15330338211039948","DOI":"10.1177\/15330338211039948","article-title":"Aberrant alteration of circulating lymphocyte subsets in small cell lung cancer patients treated with radiotherapy","volume":"20","author":"Li","year":"2021","journal-title":"Technol Cancer Res Treat"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-021-02902-x","article-title":"Effect of chemoradiotherapy on the proportion of circulating lymphocyte subsets in patients with limited-stage small cell lung cancer","volume":"70","author":"Chen","year":"2021","journal-title":"Cancer Immunol Immunother"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1667205\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T11:30:14Z","timestamp":1762428614000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1667205\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,6]]},"references-count":35,"alternative-id":["10.3389\/fonc.2025.1667205"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1667205","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,6]]},"article-number":"1667205"}}